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The number of facilities that offer tumor treatment with 
particle therapy has been increasing substantially over the 
past decades. The dose distribution deposited by ions, and 
for the heaviest, their higher biological effectiveness, make 
them more interesting to destroy localized tumors while 
sparing healthy tissues. Such an effectiveness is quantified 
through the RBE (relative biological effectiveness), which is a 
complex function of multiple parameters like cell line, cell 
cycle stage, radiation quality and irradiation conditions. 
Therefore, determining the value of RBE for every scenario is 
a challenging task that requires modeling to comply with the 
demands of a clinical environment. 
Several solutions have already been developed and a few are 
currently used in treatment planning [1-4]. Nevertheless, 
despite the progress these models have allowed, they present 
some shortcomings [5-7] that may limit their improvement. 
We present thereby a new approach that gathers some 
principles of the existing ones and addresses some of their 
weaknesses. The innovative features of NanoxTM are that it is 
fully based on statistical physics, taking in particular into 
account the fluctuations in energy deposition at multiple 
scales, and that it introduces the concept of a chemical dose. 
The latter is chosen as a parameter defined at the cell scale 
to represent the induction of cell death by “non-local” 
events as the accumulation of cellular oxidative stress or sub-
lethal lesions induced by the produced radical species. Such 
“non-local” events are complementary to the so-called 
“local” events, which take place at a very localized 
(nanometric) scale. The “local” events are considered as 
lethal since a single event can cause cell death. 
The cell survival predicted by NanoxTM for V79 cell line was 
compared with experimental results for photons, protons and 
carbon ions, and even others like neon and argon ions. A good 
agreement was found in all cases. In particular, the model is 
able to describe the effectiveness of ions, including the 
overkill effect at higher LET values. Moreover, NanoxTM can 
reproduce the typical shoulder in cell survival curves. This 
was possible due to the introduction of the “non-local” 
events, through the chemical dose, which varies with LET. It 
is worthwhile to note that such results were obtained through 
the adjustment of a reduced number of free parameters. 
The first results of NanoxTM, obtained for V79 cell line, give 
us confidence that this model has potential for application in 
a clinical scenario in the context of particle therapy. 
Although it requires the tuning of only a few free 
parameters, NanoxTM is based on solid principles and a 
thorough mathematical implementation, which renders this 
approach simple but reliable for application in clinical 
practice. 
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Purpose: The advent of personalized medicine in 
radiotherapy (RT) is accompanied by the need for accurate 
outcome prediction. The current state of predictions made 
by physicians for patient survival and toxicity after lung 
radiotherapy is comparable to flipping a coin (Oberije et 
al.,Radiother. Oncol. 2014). In order to assess the value of 
expert knowledge in prediction modelling (rather than 
directly predicting outcomes), expert-based and data-driven 
prediction models were built and compared. Models for two 
endpoints were created: 2-year survival in NSCLC non-surgery 
patients and severe dyspnea (CTCAE dyspnea scores ≥ 2) after 
RT. 
Materials/methods: Data from lung cancer patients (994 for 
dyspnea, 452 for 2-year survival) treated in clinical routine 
were collected. 10 experts (4 experts participated for both 
endpoints) selected causal links between patient, disease, 
treatment, and dose-related variables (19 for dyspnea, 17 for 
2-year survival) and the two outcomes. The selected links 
were used to construct Bayesian Networks (BN) for a 
comparison with BNs based on a data-driven algorithm. These 
models were then learned on 80% and validated on 20% of the 
patient data. Discrimination in the validation data sets is 
assessed by the Area under the Curve (AUC). 
